Laquinimod, an upcoming oral immunomodulatory agent for treatment of multiple sclerosis. Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting multiple sclerosis (RRMS). Although the mode of action of laquinimod remains to be fully elucidated, current knowledge indicates that laquinimod exerts beneficial activities both on the peripheral immune system and within the central nervous system (CNS). The immunomodulatory properties have been deciphered primarily from studies of laquinimod in the animal model of multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).
GlobalResearch at UCSF presents the broad scope of health research that is being conducted by UCSF researchers worldwide